The Antioxidant and Anti-lipidemic Potential of Angiotensin-converting Enzyme Inhibitor (Ramipril) in L-NAME Hypertensive Rats.

Abstract

Introduction: Hypertension is associated with oxidative disturbances and often coexists with metabolic disorders like hyperlipidemia. Some antihypertensive drugs, particularly angiotensin- converting enzyme (ACE) inhibitors, offer benefits beyond lowering blood pressure by addressing related conditions. This study aimed to investigate the effects of ACE inhibitors on oxidative stress and dyslipidemia induced by L-NAME hypertension in rats.

Methods: Fifteen male Wistar rats (150-170 g) were divided into three groups. Group 1 received 10 mL/kg distilled water (control), while Groups 2 and 3 were orally administered 60 mg/kg of L-NAME (L-NAME60) for eight weeks to induce hypertension. After this period, Group 2 continued to receive L-NAME60 plus distilled water (HYP), and Group 3 received L-NAME60 plus ramipril (10 mg/kg) (RMHYP) for an additional five weeks. Blood pressure was measured using the tail-cuff method. Serum oxidative stress markers and lipid profiles were analyzed by spectrophotometry.

Results: The blood pressure significantly decreased in RMHYP compared to HYP. Malondialdehyde concentration significantly decreased, and antioxidant enzyme levels significantly increased in RMHYP compared to HYP. Serum lipid profiles showed a significant decrease in total cholesterol and triglycerides, as well as atherogenic indices, but a significant increase in highdensity lipoprotein cholesterol levels in RMHYP compared to HYP.

Discussion: This research shows that ramipril not only lowers blood pressure but also significantly reduces oxidative stress and dyslipidemia in L-NAME hypertensive rats, indicating its potential as an effective treatment for metabolic syndrome.

Conclusion: The findings of this study demonstrate that angiotensin-converting enzyme inhibitors (ramipril) have the ability to act as both an antioxidant and an anti-dyslipidemic agent in hypertensive conditions.